Differentiation of the clinical features of psoriatic arthritis and fibromyalgia

摘要

Vfe thank Xie and colleagues for their comments1 on our article2 and for applying expertise to this question of interleukin 22 (IL-22) as a possible therapeutic target in rheumatoid arthritis (RA) and as a promising candidate biomarker.Novel cytokines have emerged recently as contributing to the patho-genesis of autoimmune diseases. Knowledge about the role of IL-22 in autoimmune diseases is increasing and may reveal new therapeutic options for modulation of this cytokine. The role of IL-22 has been investigated in other inflammatory autoimmune diseases, such as psoriasis3 and psoriatic arthritis4, systemic sclerosis5, and systemic lupus erythematosus.